Ibandronate has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


ibandronate studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
BON103593 IV A one-year, parallel, placebo-controlled, double-blind, randomized study to assess the effect of monthly 150 mg oral ibandronate dosing versus placebo on bone quality and strength at the proximal femur in women with osteoporosis.
SB-743830/002 I An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 150 mg Ibandronate to 3 x 50 mg Tablets of Ibandronate
SB-743830/003 I An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 100mg Ibandronate to 2 x 50 mg Tablets of Ibandronate